Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Brufsky

Showing results (51-60 of 193) with videos related to

Pageof 20
Sort By:
International Journal of Women'S Health|August 8, 2012
Patient preferences for chemotherapies used in breast cancerKathleen Beusterien, Jessica Grinspan, Thomas Tencer, et al.
Cancers|January 11, 2022
Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast CancerJuan Luis Gomez Marti, Adam Brufsky, Alan Wells, et al.
Cancers|April 14, 2025
Deep Learning: A Heuristic Three-Stage Mechanism for Grid Searches to Optimize the Future Risk Prediction of Breast Cancer Metastasis Using EHR-Based Clinical DataXia Jiang, Yijun Zhou, Chuhan Xu, et al.
Cancer Informatics|February 22, 2014
A new method for predicting patient survivorship using efficient bayesian network learningXia Jiang, Diyang Xue, Adam Brufsky, et al.
Breast Cancer Research : BCR|November 22, 2018
Statin drugs to reduce breast cancer recurrence and mortalityColin H Beckwitt, Adam Brufsky, Zoltán N Oltvai, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 5, 2008
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) casesMamatha Chivukula, Rohit Bhargava, Adam Brufsky, et al.
Targeted Oncology|August 2, 2021
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Breast (Edinburgh, Scotland)|March 26, 2025
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysisRachel M Layman, Xianchen Liu, Benjamin Li, et al.
Targeted Oncology|October 15, 2021
Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Clinical Breast Cancer|September 3, 2005
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancerAdam Brufsky, Barry Lembersky, Kathy Schiffman, et al.
Pageof 20

Showing results (51-60 of 193) with videos related to

Sort By:
Pageof 20
International Journal of Women'S Health|August 8, 2012
Patient preferences for chemotherapies used in breast cancerKathleen Beusterien, Jessica Grinspan, Thomas Tencer, et al.
Cancers|January 11, 2022
Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast CancerJuan Luis Gomez Marti, Adam Brufsky, Alan Wells, et al.
Cancers|April 14, 2025
Deep Learning: A Heuristic Three-Stage Mechanism for Grid Searches to Optimize the Future Risk Prediction of Breast Cancer Metastasis Using EHR-Based Clinical DataXia Jiang, Yijun Zhou, Chuhan Xu, et al.
Cancer Informatics|February 22, 2014
A new method for predicting patient survivorship using efficient bayesian network learningXia Jiang, Diyang Xue, Adam Brufsky, et al.
Breast Cancer Research : BCR|November 22, 2018
Statin drugs to reduce breast cancer recurrence and mortalityColin H Beckwitt, Adam Brufsky, Zoltán N Oltvai, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 5, 2008
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) casesMamatha Chivukula, Rohit Bhargava, Adam Brufsky, et al.
Targeted Oncology|August 2, 2021
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Breast (Edinburgh, Scotland)|March 26, 2025
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysisRachel M Layman, Xianchen Liu, Benjamin Li, et al.
Targeted Oncology|October 15, 2021
Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical PracticeAdam Brufsky, Xianchen Liu, Benjamin Li, et al.
Clinical Breast Cancer|September 3, 2005
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancerAdam Brufsky, Barry Lembersky, Kathy Schiffman, et al.
Pageof 20